Metabolic associated fatty liver disease
Conditions
Interventions
Treatment group:Lifestyle intervention and oral administration of granules from single decoction of Ling Gui Zhu Gan Tang
control group:Lifestyle intervention and simulated oral administration of lyingguizhugan Decoction granules
Sponsors
Jiangsu Hospital of integrated traditional Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Years and ranged from 18-70 years Meets the diagnostic criteria of Western medicine for metabolic related fatty liver disease Patients had serum ALT and (or) ast and GGT not more than 2.5 times the upper limit of normal Informed consent and good compliance
Exclusion criteria
Exclusion criteria: 1.Combined alcoholic liver disease, chronic hepatitis C, autoimmune liver disease, and Wilson's disease can lead to specific liver diseases with fatty liver 2. Fatty liver due to drugs (e.g., tamoxifen, amiodarone, valproate, methotrexate, glucocorticoids, etc.), total parenteral nutrition, inflammatory bowel disease, hypothyroidism, Cushing's syndrome, lipoprotein deficiency and some syndromes associated with insulin resistance (lipoatrophic diabetes, Mauriac syndrome) 3. Patients with severe primary diseases of the cardio cerebrovascular, hepatic, renal and haematopoietic systems, malignancies, other severe comorbidities or psychiatric illness were included 4. Patients who are using therapeutic agents for NAFLD (including Chinese herbal decoctions, Chinese patent medicines, and chemicals) 5. Patients with complicated other gastrointestinal diseases, such as intestinal polyps, bowel cancer, etc., and uneventful vital signs, complicated by intestinal perforation, lower gastrointestinal bleeding, colorectal cancer, etc., requiring surgical treatment 6. Patients taking or currently taking antibiotics within nearly 1 month 7. Those with known allergy to the constituent ingredients of the study drug or an allergic constitution 8. Pregnant and lactating women, and women with potential pregnancies who refused to maintain the contraception recognized by the investigator throughout the study 9. Nearly 3 months of use of drugs affecting insulin sensitivity such as pioglitazone, metformin, etc 10. Had participated in other clinical trials or were participating in other clinical trials in nearly 3 months 11.Unable to perform therapeutic lifestyle changes as instructed 12.Patients who did have a history of substance abuse or did have other conditions not eligible for enrollment were suspected 13.Cases with incomplete data supplement Presence of any of the above, this patient could not be included in the study analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine transaminase;Aspartate aminotransferase;gamma-glutamyl transpeptidase;Blood lipids;Liver color ultrasound;Blood sugar;Accumulated fat content in liver; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine;Glycosylated hemoglobin;Immune and inflammatory markers;Clinical symptom score of traditional Chinese medicine;Non-invasive score of fibrosis; | — |
Countries
China
Contacts
Public ContactChao Liu
Jiangsu Hospital of integrated traditional Chinese and Western Medicine
Outcome results
None listed